Multicenter European Registry for Patients with AAA Undergoing EVAR Evaluating the Performance of the 36-mm-Diameter Endurant Stent-Graft.
Title | Multicenter European Registry for Patients with AAA Undergoing EVAR Evaluating the Performance of the 36-mm-Diameter Endurant Stent-Graft. |
Publication Type | Journal Article |
Year of Publication | 2017 |
Authors | Valdivia, A. Reyes, Pitoulias G., Criado F. J., Torsello G., Gandarias C., Austermann M., Pitoulias A. G., & Donas K. |
Journal | Cardiovasc Intervent Radiol |
Volume | 40 |
Issue | 10 |
Pagination | 1514-1521 |
Date Published | 2017 Oct |
ISSN | 1432-086X |
Keywords | Aged, Aortic Aneurysm, Abdominal, Blood Vessel Prosthesis, Blood Vessel Prosthesis Implantation, Computed Tomography Angiography, Endovascular Procedures, Europe, Female, Humans, Male, Prospective Studies, Prosthesis Design, Registries, Retrospective Studies, Stents, Time Factors, Treatment Outcome |
Abstract | INTRODUCTION: The use of and results with the Endurant stent-graft have been reported extensively. However, there has been little if any focus placed on performance and outcomes when a 36-mm-diameter device is used.METHODS: Data were collected and retrospectively analyzed on EVAR patients treated with a 36-mm-diameter Endurant device at 3 European academic vascular centers between 2007 and 2015. Primary endpoints were the absence of type Ia endoleak in the early and mid-term follow-up period, and aneurysm sac stabilization or shrinkage. Secondary endpoints were 30-day mortality, overall survival and secondary interventions. Subgroup analysis of outcomes in the on-label (ONL) versus off-label (OFL) device use cohorts was also performed.RESULTS: Seventy-three patients were included in the study. Mean follow-up was 30.1 ± 16.2 months. Mean aortic neck diameter was 29.5 ± 1.9. Primary technical success was achieved in 69 patients (94.5%). Five patients (6.8%) were found to have developed a type Ia endoleak, 3 during the first month, and the other 2 at 2 years. Overall EVAR-related mortality was 4.1% (n = 3). Subgroup analysis focused on the OFL cohort (n = 44) versus the ONL patients (n = 29). Two of the OFL patients (4.5%) had a type Ia endoleak, and 3 (10.3%) in the ONL group.CONCLUSION: The use of the largest diameter Endurant stent-graft device emerges as a reasonable option for EVAR treatment of AAA featuring a large-diameter proximal neck. Assessment of a larger group of patients followed in the long term will be necessary for a more definitive statement on such strategy. |
DOI | 10.1007/s00270-017-1665-6 |
Alternate Journal | Cardiovasc Intervent Radiol |
PubMed ID | 28462441 |